Reta 30mg
Supports weight loss and metabolic health.
$303
An experimental triple agonist acting on three key hormonal pathways for weight, metabolism, and cardiometabolic health.
28.3%
Avg. body weight reduction at 12mg over 80 weeks (Phase 3)
- GLP-1: regulates appetite and satiety.
- GIP: boosts metabolism and energy utilization.
- Glucagon: increases energy expenditure and fat oxidation.
- Phase 3 trial (Eli Lilly, 2,339 adults, 80 weeks): average weight loss of 19.0% (4mg), 25.9% (9mg) and 28.3% (12mg), vs. 2.2% for placebo.
- 45.3% of patients on the 12mg dose lost ≥30% of body weight; effects sustained through 104 weeks.
- Most common side effects were gastrointestinal (nausea 28.6%, diarrhea 25.2%, constipation 23.8%), mostly mild to moderate.
1
Dosing schedule
Concentration
10 mg/ml, total 3 ml, total 30 mg
Frequency
See dosage
Dose
25 clicks once a week for the first two weeks; from the third week onward, 25 clicks twice a week.
Duration
1 Month
Break
1 Month
A multi-receptor agonist peptide targeting GLP-1, GIP, and glucagon pathways, aiding in weight loss and metabolic regulation. Investigational — not approved by the FDA or any regulatory agency. Source: Eli Lilly Phase 3 results, May 21, 2026.
For research use only. Not for human consumption. Not evaluated by the FDA.